Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treat ent Delivery: A Multicentre International Analysis of 1384 Patients Matthew R. Wilson , Toby A. Eyre , Amy A. Kirkwood , Nicole Wong Doo , Carole Soussain , Sylvain Choquet , Nicolas Martinex-Calle , Gavin Preston , Matthew J. Ahearne , Elisabeth Schorb , Marie-Pierre Moles-Moreau , Matthew Ku , Chiara Rusconi , Jahanzaib Khwaja , Mayur Narkhede , Katharine L. Lewis , Teresa Calimeri , Eric Durot , Loic Renaud , Andreas Kiesbye Ovlisen , Graham McIlroy , Tim Ebsworth , Johnathon Elliot , Anna Santarsiere , Laure Ricard , Nimish Shah , Qin Liu , Adam Zayac , Francesco Vassallo , Laure Lebras , Louise Roulin , Naelle Lombion , Kate Manos , Ruben Fernandez , Nada Hamad , Alberto Lopez-Garcia , Deirdre O'Mahony , Praveen Gounder , Nathalie Forgeard , Charlotte Lees , Kossi Agbetiafa , Tim Struesmann , Thura Win Htut , Aline Clavert , Hamish W. Scott , Anna Guidetti , Brett R. Barlow , Jeffrey Smith , Tarec Christoffer El-Galaly , Chan Yoon Cheah , Andres J. M. Ferreri , Fiona Miall , Christopher P. Fox , Kate Cwynarski , Pamela McKay Blood(2021)
Key words
frontline dlbcl therapy, high dose methotrexate, cns relapse, treatment delivery
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper